Patents by Inventor Kangyun Wu

Kangyun Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
    Publication number: 20230192728
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Application
    Filed: July 13, 2022
    Publication date: June 22, 2023
    Applicant: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
    Patent number: 11407771
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 9, 2022
    Assignee: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
    Publication number: 20210214378
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Applicant: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu